1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
6
Rare Diseases
across 11 areas
0
News (30d)
Quiet
ExperGen Drug Development GmbH is a company with 1 orphan drug designation across 6 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| B-cell neoplasm | miltefosine | Des.TrialAppr. |
| primary cutaneous T-cell non-Hodgkin lymphoma | miltefosine | Des.TrialAppr. |
| primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma | miltefosine | Des.TrialAppr. |
| primary cutaneous anaplastic large cell lymphoma | miltefosine | Des.TrialAppr. |
| primary cutaneous follicle center lymphoma | miltefosine | Des.TrialAppr. |
| primary cutaneous lymphoma | miltefosine | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
4
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
4
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
0
affecting portfolio